Welcome to our dedicated page for Merit Med Sys news (Ticker: MMSI), a resource for investors and traders seeking the latest updates and insights on Merit Med Sys stock.
Overview
Merit Medical Systems, Inc. (NASDAQ: MMSI) is a globally recognized manufacturer and distributor of advanced medical devices that are instrumental in diagnostic, cardiology, and interventional radiology procedures. With a long-standing history in the development of disposable medical tools, Merit operates from its headquarters in South Jordan, Utah and serves a worldwide customer base through a combination of direct sales and distributor networks. The company is renowned for its commitment to precision, quality, and innovation in the medical device industry, continuously enhancing its product portfolio to meet the evolving demands of minimally invasive procedures.
Products and Services
At its core, Merit Medical Systems develops, manufactures, and markets a diverse range of proprietary disposable medical devices. These devices are vital components in procedures such as angioplasty, stent placement, discography, and embolization therapies. Key product categories include:
- Inflation and Angioplasty Devices: Engineered for precision in opening narrowed vessels, these devices support interventions such as stent placement and discography.
- Diagnostic and Therapeutic Catheters: Designed for use in both diagnostic and therapeutic settings in cardiology and radiology, offering versatility and reliability.
- Guide Wires: Essential for the careful placement of balloon angioplasty catheters, ensuring safe navigation through coronary arteries.
- Embolic Devices: Including innovative embolic products that enhance the accuracy and efficiency of procedures that occlude blood vessels to manage bleeding or treat abnormal tissue growth.
- Ancillary Products and Custom Kits: These encompass angiography accessories and specifically tailored angiography kits that support a wide range of clinical applications.
The company’s product development not only addresses the critical needs of diagnostic and interventional procedures but also extends to applications in oncology, critical care, and endoscopy. By integrating state-of-the-art design with robust manufacturing processes, Merit Medical ensures that its products deliver reliable performance and improved patient outcomes in fast-paced clinical environments.
Market Position and Business Model
Merit Medical Systems stands out within the competitive landscape by focusing on innovation, quality, and comprehensive clinical support. The company generates revenue primarily through direct sales channels in the United States and Europe as well as via a global network of distributors. This diversified sales model allows Merit to directly engage with hospitals, clinics, and physicians, ensuring that its advanced medical devices are consistently positioned as trusted solutions in critical care. By maintaining strict quality standards and achieving key regulatory clearances, Merit has built a reputation for excellence and continues to bolster its market position through strategic product portfolio expansions and acquisitions that enhance its capabilities in high-margin segments such as electrophysiology and cardiac rhythm management.
Research, Innovation, and Clinical Support
Innovation is at the forefront of Merit Medical’s strategy. The company invests in research and development to bring new product solutions to market, supported by extensive clinical trials and regulatory reviews. Merit collaborates with medical professionals and thought leaders to design devices that not only meet current clinical needs but also address emerging challenges in patient care. This focus on innovation is complemented by a strong clinical support team that works closely with healthcare practitioners to provide education, training, and technical assistance, ensuring that the advantages of Merit’s devices are fully realized in real-world clinical settings.
Competitive Landscape
Operating in a dynamic and highly competitive medical device market, Merit Medical Systems differentiates itself by combining technical expertise with a deep understanding of clinical practices. While the industry features multiple players offering various medical technologies, Merit’s specialization in interventional and diagnostic procedures, along with its commitment to continuous innovation and quality assurance, establishes it as an authoritative and trusted partner in patient care. The company’s ongoing investments in new technologies and strategic acquisitions further strengthen its competitive position, supporting its role as a key contributor to advancements in minimally invasive treatment.
Regulatory Excellence and Global Reach
Merit Medical’s success is underpinned by its adherence to stringent regulatory standards. With multiple products gaining clearance or approval from major regulatory agencies, the company demonstrates its commitment to safe and effective medical device manufacturing. This regulatory excellence, combined with a robust global distribution network, enables Merit to serve a broad spectrum of healthcare institutions and maintain enduring partnerships with clinicians worldwide.
Conclusion
In summary, Merit Medical Systems, Inc. is a pivotal force in the field of healthcare technology. Through its innovative medical devices, unwavering commitment to quality, and strategic global presence, Merit empowers healthcare professionals to deliver more reliable, precise, and minimally invasive treatments. The company continues to be a cornerstone in advancing interventional, diagnostic, and therapeutic procedures, reinforcing its position as a trusted partner within the medical community.
SOUTH JORDAN, Utah, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Merit Medical Systems (NASDAQ: MMSI) will hold an investor call today to discuss multi-year financial targets from 2020 to 2023. Key targets include a compound annual growth rate (CAGR) of 5%-7% in revenue, a GAAP operating margin of 13.7%-17.0%, and a non-GAAP operating margin of 18%-21%. The company estimates 2020 net revenue between $950 million and $959 million, a decline from $994.9 million in 2019. GAAP net loss is forecasted between $(11.8) million and $(15.0) million.
Merit Medical Systems reports Q3 2020 revenue of $244.0 million, a 0.4% increase from Q3 2019. Core revenue fell (0.1)% on a constant currency basis, while GAAP loss per share improved to $(0.05), from $(0.06). Non-GAAP EPS rose 50% to $0.42. GAAP gross margin decreased from 42.8% to 41.8%, but non-GAAP gross margin fell from 48.1% to 47.0%. Cash on hand increased to $44.6 million, with long-term debt down to $358 million. Fiscal 2020 revenue guidance is estimated at $950-$959 million, reflecting a 3.5%-4.5% annual decline.
Merit Medical Systems (NASDAQ: MMSI) announced a settlement with the U.S. Department of Justice and Health and Human Services, opting to pay $18 million to avoid litigation costs. The settlement does not imply wrongdoing, as Merit denies the allegations. The company aims to refocus on its core mission of customer service in healthcare.
Founded in 1987, Merit specializes in proprietary disposable medical devices for various medical procedures, serving hospitals globally with a workforce of around 6,000 personnel across numerous locations.
Merit Medical Systems (NASDAQ: MMSI) announces financial results for Q3 2020 on October 28, 2020, after market close. An investor call will follow on November 10, 2020, to introduce multi-year financial targets for growth and profitability. The company, a major player in medical devices for cardiology, oncology, and other sectors, will host a Q&A session during the investor call, accessible via phone and live webcast.
Merit Medical Systems (NASDAQ: MMSI) announced participation in four investment conferences in September 2020. On September 9, CEO Fred P. Lampropoulos and CFO Raul Parra will engage in one-on-one meetings at the Barrington Research Virtual Fall Investment Conference. The following day, Lampropoulos will also host meetings at the Wells Fargo Virtual Healthcare Conference. Parra is set to present at the Baird's Global Healthcare Conference on September 10 and will conduct meetings. Lastly, both executives will present at Sidoti’s Fall 2020 Virtual Investor Conference on September 24.
Merit Medical Systems reported Q2 2020 revenue of $218.4 million, a 14.5% decrease from the previous year. The company faced a GAAP loss per share of $(0.34), down from $0.12 in Q2 2019. Non-GAAP EPS was $0.31, compared to $0.42 last year. Their free cash flow for the quarter was $32 million. Merit encountered challenges during the COVID-19 pandemic but continued operations as an essential provider. The company received CE mark for the WRAPSODY™ Stent and FDA approval for the WAVE trial, indicating potential growth prospects despite current uncertainties.
Merit Medical Systems, Inc. (NASDAQ: MMSI) will announce its financial results for Q2 2020 after the market closes on July 29, 2020. Following this, an investor conference call is scheduled for the same day at 5:00 p.m. Eastern. Interested parties can participate by calling (844) 578-9672 domestically or (508) 637-5656 internationally, and a live webcast will be available on their website. Founded in 1987, Merit specializes in disposable medical devices used in various medical fields, employing around 6,000 people globally.
Merit Medical Systems (NASDAQ: MMSI) has reached an agreement with the Department of Justice to resolve its marketing practices investigation, expecting to pay $18 million while denying the allegations. CEO Fred P. Lampropoulos stated that this resolution is beneficial for the business, allowing the company to refocus on customer service. The final settlement details will be released once the documents are finalized. Merit, established in 1987, specializes in developing and distributing disposable medical devices across various medical fields, employing around 6,000 individuals globally.
Merit Medical Systems, Inc. (NASDAQ: MMSI) announced the nomination of three independent directors—Lonny Carpenter, David Floyd, and James Hogan—for election at the upcoming 2020 Annual Meeting on June 22. The new appointments aim to enhance shareholder value and add industry experience. The current board members Nolan Karras, David Liu, and Lynne Ward will not seek re-election, while Franklin Miller will resign post-meeting. Additionally, an Operating Committee will be formed to establish operating margin targets. Starboard Value LP, which holds 8.7% of shares, supports these changes.
Merit Medical Systems (NASDAQ: MMSI) announced on May 26, 2020, that it has received the CE mark for its WRAPSODY™ Endovascular Stent Graft System from the British Standards Institution (BSI). This device aims to treat stenosis or occlusion in hemodialysis patients and is set to be introduced in Europe as procedures resume post-COVID-19. Merit has worked on this product for nearly eight years and recently completed the WRAPSODY FIRST study with 46 patients. The company also submitted an IDE application to the FDA for its upcoming WAVE Pivotal Study.
FAQ
What is the current stock price of Merit Med Sys (MMSI)?
What is the market cap of Merit Med Sys (MMSI)?
What core products does Merit Medical Systems, Inc. offer?
In which clinical areas does Merit specialize?
How does Merit Medical generate revenue?
What sets Merit Medical apart in the competitive medical device market?
How does the company ensure the quality and safety of its products?
What role does research and development play at Merit Medical?
How does Merit Medical support healthcare professionals?
What is Merit Medical's global market presence?
